Jeff Yass’s Purple Biotech PPBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-154
Closed -$43.1K 12749
2023
Q2
$43.1K Buy
154
+8
+5% +$2.87K ﹤0.01% 11394
2023
Q1
$51.4K Sell
146
-542
-79% -$203K ﹤0.01% 11693
2022
Q4
$190K Buy
688
+191
+38% +$73.3K ﹤0.01% 10212
2022
Q3
$202K Buy
497
+223
+81% +$104K ﹤0.01% 10824
2022
Q2
$131K Buy
274
+30
+12% +$18K ﹤0.01% 11200
2022
Q1
$194K Sell
244
-89
-27% -$57.4K ﹤0.01% 11271
2021
Q4
$259K Sell
333
-599
-64% -$510K ﹤0.01% 10838
2021
Q3
$850K Sell
932
-381
-29% -$369K ﹤0.01% 7985
2021
Q2
$1.28M Buy
1,313
+759
+137% +$697K ﹤0.01% 7069
2021
Q1
$458K Buy
+554
New +$517K ﹤0.01% 9687

Other funds holding PPBT

Jeff Yass's PPBT Position: Q2 2026 in Review

Jeff Yass reduced its Purple Biotech (PPBT) stake by 76% in Q2 2026, selling an estimated $137K and leaving 12,847 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #13031.

Jeff Yass first reported a position in PPBT in Q4 2017 and has held it in 13 quarters since. The position peaked at $309K in Q4 2025. 13 funds tracked by Wall St. Rank hold PPBT as of Q2 2026.

  • Jeff Yass held 12,847 shares of Purple Biotech worth $21.6K as of Q2 2026.
  • Jeff Yass sold 40,556 Purple Biotech shares in Q2 2026, an estimated $137K.
  • Purple Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #13031 holding.
  • Jeff Yass first reported a position in Purple Biotech in Q4 2017 and has held it in 13 quarters since.
  • Jeff Yass's Purple Biotech position peaked at $309K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Purple Biotech as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.